Takeda Pharmaceutical Company Limited

Kenichiro Kiyoshima

Kenji Nakamura

Masafumi Misaki

Megumi Ikeda

Tetsuya Kawano

Hiroto Bando

Yoshihiro Omachi

Junya Nomura

Shohei Horiuchi

Tomomi Sato

Shinichiro Nakai

The present invention provides a preparation containing pioglitazone or a salt thereof as an active ingredient, which shows high bioavailability of pioglitazone and less interindividual variation in blood drug concentration, as well as a preparation with suppressed color change during preservation. The preparation contains a core containing a pharmaceutically acceptable organic acid with water solubility at 20&#xb0; C. of not less than 10 mg/mL and pK(a negative common logarithm of the first acid dissociation constant K) at 25&#xb0; C. of not more than 5, and a coating layer containing pioglitazone or a salt thereof. The coating layer may further contain mannitol or trehalose.

Coated preparation

A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts:

Solid preparation comprising alogliptin and pioglitazone

The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from 'a solid preparation containing only an insulin sensitizer as an active ingredient'. The solid preparation comprises 'a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol' and &#x201c;a part containing an active ingredient other than an insulin sensitizer&#x201d;.

Solid preparation

Growing community of inventors

Osaka, Japan

Kenichiro Kiyoshima